BIOCRYST PHARMACEUTICALS INC 8-K/A

What Happened
BioCryst Pharmaceuticals, Inc. announced it completed the merger with Astria Therapeutics, Inc. on January 23, 2026 (the Closing Date), with Axel Merger Sub, Inc. merging into Astria and Astria surviving as a wholly owned subsidiary of BioCryst. BioCryst previously disclosed the conditional appointment of Jill C. Milne, Ph.D., to its board on October 14, 2025; those conditions were satisfied at closing and her board appointment became effective. This amendment (Amendment No. 1) to the earlier Form 8-K reports that, effective as of the Closing Date, the board also appointed Dr. Milne to BioCryst’s Compensation and Science Committees.

Key Details

• Merger closed on January 23, 2026: Merger Sub merged with and into Astria; Astria is now a wholly owned subsidiary of BioCryst.
• Initial conditional board appointment for Jill C. Milne was disclosed on October 14, 2025; appointment became effective at closing.
• On January 20, 2026 the Board appointed Dr. Milne to the Compensation and Science Committees, effective as of the Closing Date.
• Filing relates to Item 5.02 (Election of Directors) and is an amendment to the Initial 8-K.

Why It Matters
The merger expands BioCryst’s corporate structure by bringing Astria into the company as a wholly owned subsidiary, which may affect BioCryst’s product portfolio and pipeline integration over time. The formal addition of Dr. Jill C. Milne to the board — and to the Compensation and Science Committees — updates corporate governance and adds scientific and compensation oversight at the board level. Investors should note the completed transaction and the governance changes reported in this Item 5.02 filing when assessing company strategy and leadership.